Ablynx – Catalyst next month, Good midterm buy
- Ablynx is preparing for a potential first launch of its lead drug candidate caplacizumab in 1H2018, with phase 3 data readout possibly next month.
- Ablynx has more than 45 proprietary and partnered programmes in development in various therapeutic areas
- The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co.
The full post is available to investor members only. Subscribe here.